scispace - formally typeset
Open AccessJournal ArticleDOI

Corrigendum to:: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)

Reads0
Chats0
About
This article is published in European Heart Journal.The article was published on 2017-11-24 and is currently open access. It has received 11 citations till now. The article focuses on the topics: Proprotein convertase & Kexin.

read more

Citations
More filters
Journal ArticleDOI

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

TL;DR: Evaluating the evidence for the use of LDL subfractions, or LDL-P, when assessing CVD risk in patients for whom PCSK9 inhibitors are considered as a lipid-lowering therapy finds no studies have proven that these measurements improve clinical outcomes.
Journal ArticleDOI

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

TL;DR: Current knowledge about antibody-mediated PCSK9 inhibition as add-on therapy to statin and the clinical potential that may be expected are discussed.
Journal ArticleDOI

The year in cardiology 2017: prevention.

TL;DR: This paper presents a meta-analysis of data from the Danish General Population Study and the German Center of Cardiovascular Research (DZHK) that shows clear trends in mortality and morbidity among patients with a history of heart attack and stroke.

Familial hypercholesterolaemia: a common cause of premature coronary disease in the community and a paradigm for the practice of precision medicine

Jing Pang, +1 more
TL;DR: The science of FH is presented, a review of major advances in the care of Fh in the form of a “how to” guide and an overview of initiatives for closing the worldwide gaps in care are presented.
Related Papers (5)

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

François Mach, +95 more
- 01 Jan 2019 -